SI-BONE, Inc. (NASDAQ:SIBN) Insider Anthony J. Recupero Sells 5,461 Shares

SI-BONE, Inc. (NASDAQ:SIBN) insider Anthony J. Recupero sold 5,461 shares of the stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $17.69, for a total value of $96,605.09. Following the sale, the insider now owns 203,835 shares of the company’s stock, valued at $3,605,841.15. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

SI-BONE Stock Performance

SIBN stock traded up $0.50 during midday trading on Monday, reaching $18.04. 230,933 shares of the company’s stock traded hands, compared to its average volume of 355,422. The company has a 50-day moving average price of $18.93 and a two-hundred day moving average price of $22.72. The company has a debt-to-equity ratio of 0.21, a quick ratio of 9.74 and a current ratio of 10.89. SI-BONE, Inc. has a 52 week low of $11.14 and a 52 week high of $29.51. The firm has a market capitalization of $730.64 million, a PE ratio of -15.16 and a beta of 0.99.

Analyst Ratings Changes

A number of research firms have issued reports on SIBN. Morgan Stanley cut their price target on SI-BONE from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday, November 7th. Cantor Fitzgerald cut their price target on SI-BONE from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday, November 7th. Needham & Company LLC cut their price target on SI-BONE from $32.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, November 7th. Finally, Truist Financial cut their price target on SI-BONE from $33.00 to $31.00 and set a “buy” rating for the company in a research note on Tuesday, August 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $27.17.

Institutional Investors Weigh In On SI-BONE

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its position in shares of SI-BONE by 37.9% during the 1st quarter. JPMorgan Chase & Co. now owns 167,745 shares of the company’s stock valued at $3,791,000 after purchasing an additional 46,086 shares in the last quarter. HighTower Advisors LLC purchased a new position in shares of SI-BONE during the 1st quarter valued at $220,000. MetLife Investment Management LLC grew its position in shares of SI-BONE by 54.2% during the 1st quarter. MetLife Investment Management LLC now owns 18,825 shares of the company’s stock valued at $425,000 after purchasing an additional 6,615 shares in the last quarter. Rhumbline Advisers grew its position in shares of SI-BONE by 8.3% during the 1st quarter. Rhumbline Advisers now owns 32,233 shares of the company’s stock valued at $728,000 after purchasing an additional 2,476 shares in the last quarter. Finally, BlackRock Inc. grew its position in shares of SI-BONE by 0.4% during the 1st quarter. BlackRock Inc. now owns 2,709,443 shares of the company’s stock valued at $61,233,000 after purchasing an additional 9,645 shares in the last quarter.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma.